Company Ticker News October 19, 2021Biogen sales face pressure from slow uptake of Alzhiemer's drug 0 0 Share
Press Release October 19, 2021Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022 0 0 Share
Company Ticker News October 18, 2021Is Biogen stock a buy or sell as ALS study falls short of primary endpoints? 0 0 Share
Company Ticker News October 18, 2021Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial 0 0 Share
Company Ticker News October 18, 2021Biogen's Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder Trial 0 0 Share
Press Release October 17, 2021Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS 0 0 Share
Company Ticker News October 15, 20213 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More 0 0 Share
Company Ticker News October 13, 2021Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for 0 0 Share
Press Release October 13, 20213 Top Healthcare Stocks That Could Rise More Than 40% in 12 Months 0 0 Share
